TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 AMD
Advanced Micro Devices
-- 119.210 OXY
Occidental Petroleum
-- 47.130 
NEWS TODAY
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Plus Therapeutics (PSTV) will present Phase 1 interim data for its ReSPECT-LM trial at the 2024 San Antonio Breast Cancer Symposium. The presentation will focus on Rhenium (186Re) Obisbemeda treatment for leptomeningeal metastases (LM) in breast cancer patients.
The presentation, led by Dr. Andrew Brenner from the University of Texas Health Science Center, is scheduled for December 13, 2024. LM is a rare but serious cancer complication affecting the cerebrospinal fluid and leptomeninges, with breast cancer being the most common primary cancer leading to LM. The condition affects 3-5% of breast cancer patients and has a poor prognosis, with 1-year and 2-year survival rates of only 7% and 3%, respectively. Currently, there are no FDA-approved therapies specifically for LM.
The presentation, led by Dr. Andrew Brenner from the University of Texas Health Science Center, is scheduled for December 13, 2024. LM is a rare but serious cancer complication affecting the cerebrospinal fluid and leptomeninges, with breast cancer being the most common primary cancer leading to LM. The condition affects 3-5% of breast cancer patients and has a poor prognosis, with 1-year and 2-year survival rates of only 7% and 3%, respectively. Currently, there are no FDA-approved therapies specifically for LM.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment